- Developed for India and other
countries where patient access to care with radiotherapy is
challenged and where versatility and ease of use are a high
priority
- Drives the next phase of company's strategic plan to expand its
portfolio of helical radiation therapy delivery systems
MADISON,
Wis., Aug. 27, 2024 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today the company has
received CE Mark for Accuray Helix™, a CT-guided helical
radiotherapy system designed to provide high-performance and
high-throughput. The new system is intended for emerging markets
where access to advanced cancer care, including radiotherapy
treatments, is typically obtainable only within urban areas and
where the availability of linear accelerators per million
population is well below the World Health Organization recommended
guidelines. Accuray Helix offers a solution for clinical teams that
require short treatment times and cost effectiveness to establish a
care path for patients in non-urban communities who previously had
limited options.
Radiotherapy is a fundamental component of cancer
care1 and can be used in the treatment of
localized disease, recurrent or metastatic cancer. An estimated 50
percent of people with cancer would benefit from radiation
therapy2 either as their sole care
option or along with other modalities such as surgery, chemotherapy
or immunotherapy.
"While the demand for cancer services is increasing globally,
there are certain areas of the world where there continues to be
greater gaps in access to radiation medicine. India is a priority due to this disparity as
there is a significant deficit in availability of radiation therapy
systems compared to the size if its population and incidence of
cancer. Our goal with the introduction of Accuray Helix is to close
some of these gaps to patient access with our comprehensive
solutions," said Suzanne Winter,
president and CEO of Accuray. "The Accuray Helix system combines
affordability with automation and tools for enhancing the speed of
planning and delivery of radiation. We believe it will enable a
broader range of capabilities for facilities that may have
resources and staffing for only one system, enabling them to offer
state-of-the-art cancer care in their communities."
Accuray Helix delivers precise, targeted radiation treatments,
an important option for the routine cases clinical teams see daily
in their practice including breast, cervix, head and neck,
gastrointestinal, lung and prostate. The system's flexibility and
versatility are intended to drive improvements in personalization
and patient care, while simultaneously facilitating treatment of
more patients each day, boosting productivity for clinics and
enabling them to efficiently manage the growing demand for cancer
care.
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions designed to deliver radiation
treatments for even the most complex cases—while making commonly
treatable cases even easier—to meet the full spectrum of patient
needs. We are dedicated to continuous innovation in radiation
therapy for oncology, neuro-radiosurgery, and beyond, as we partner
with clinicians and administrators, empowering them to help
patients get back to their lives, faster. Accuray is headquartered
in Madison, Wisconsin, with
facilities worldwide. To learn more, visit www.accuray.com or
follow us on Facebook, LinkedIn, X, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to expectations related to
Accuray Helix and its effect on the field of radiation oncology and
clinical practice, expectations with respect to the markets in the
company plans to offer Accuray Helix, clinical applications,
clinical results, patient experiences and patient outcomes These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the company's ability to achieve widespread
market acceptance of its products, including new product
innovations and releases; the company's ability to develop new
products or improve existing products to meet customers' needs; the
company's ability to anticipate or keep pace with changes in the
marketplace and the direction of technological innovation and
customer demands and such other risks identified under the heading
"Risk Factors" in the company's quarterly report on Form 10-Q,
filed with the Securities and Exchange Commission (the "SEC") on
May 8, 2024, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact
Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com
1INTERNATIONAL ATOMIC ENERGY AGENCY, Radiotherapy in
Cancer Care: Facing the Global Challenge, Non-serial Publications ,
IAEA, Vienna (2017).
2Atun et al. Expanding global access to radiotherapy.
Lancet Oncol 2015; 16:1153-86.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accuray-receives-ce-mark-for-a-new-helical-radiation-delivery-system-accuray-helix-302231256.html
SOURCE Accuray Incorporated
